Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KINETIK: Pharmacokinetics of immunosuppressants after switch to Biktarvy in HIV-1 infected kidney transplant recipients
2021-004010-19Phase 4Active
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Institut de Médecine et d'Epidémiologie Appliquée. Primary endpoint: Primary: Change in calcineurin and mTOR inhibitor blood concentrations. Started Aug 2021; status: active.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2021-004010-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004010-19.